Beijing Human Zhizao Technology
Automated multiplex in-vitro diagnostic testing platforms
About Beijing Human Zhizao Technology
Beijing Human Zhizao Technology, also known as HumaDX, is a medical technology company established in 2021. The company focuses on developing and providing automated, high-throughput diagnostic solutions for clinical laboratories, with a core competency in multiplex flow fluorescence technology. HumaDX was founded to overcome the high technical barriers and lack of full automation in the multiplex immunoassay field.
The firm's product portfolio is built on three main technology platforms: the HumaPlex full-automatic multiplex immunoassay platform, the HumaCLIA full-automatic chemiluminescence platform, and the HumaBlot full-automatic immunoblotting platform. These systems are designed to offer high-sensitivity, multi-parameter, and cost-effective testing, particularly for immunological diseases, rare diseases, and cytokines. The HumaPlex platform, for example, can simultaneously detect over 40 different parameters. The company serves clinical customers and medical centers globally, supported by a service network in over 30 provinces in China.
HumaDX has achieved significant milestones, including filing for over 30 patents and obtaining more than 170 CE certificates for its products. The company secured over 100 million RMB in a Series A funding round to facilitate commercial expansion, product registration, and clinical validation. This includes an A1 round exclusively invested by Yuanbio Venture Capital and an A2 round co-led by WenRun Investment and ShanLan Capital. Additionally, HumaDX acquired Beijing Pioneer Biotech to enhance its distribution channels in China.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 14.3/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2023 | $14M | $55M | Sunland fund · Wen's Investment | ↗ |
| SERIES A✓Equity / VC | Jan 2023 | $2.8M | $11M | Yuansheng Venture Capital | ↗ |
Growth signals
Latest recorded traffic for Beijing Human Zhizao Technology is 3.2K monthly website visits, up 424.6% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Human Zhizao Technology in the Nanjing City ecosystem
The Beijing Human Zhizao Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- YCYuansheng Venture Capital
Sunland fund- WIWen's Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Human Zhizao Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Human Zhizao Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.